RGLS Regulus Therapeutics Inc.

1.31
+0.03  (+2%)
Previous Close 1.28
Open 1.27
Price To Book -4.37
Market Cap 26918470
Shares 20,548,450
Volume 166,506
Short Ratio
Av. Daily Volume 184,187

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 enrollment has been paused due to financial conditions - noted July 5, 2018.
RG-012 - HERA
Alport Syndrome
Phase 1 trial has been paused due to unexpected observations in mouse toxicity trial.
RGLS4326
Autosomal dominant polycystic kidney disease (ADPKD)

Latest News

  1. Regulus: 1Q Earnings Snapshot
  2. Regulus Therapeutics Reports First Quarter 2019 Financial Results and Recent Updates
  3. Regulus Therapeutics Announces Closing of First Tranche of $41.8 Million Private Placement of Equity
  4. Regulus Therapeutics Announces Restructuring of Term Loan
  5. Regulus Therapeutics Announces Private Placement of Equity
  6. Will Regulus (RGLS) Report Negative Q1 Earnings? What You Should Know
  7. Regulus to Present Preclinical Efficacy Data Highlighting Potential of Novel Treatment for Nonalcoholic Steatohepatitis at The International Liver Congress™ 2019
  8. Four Healthcare Stocks Getting a Boost on Thursday
  9. Regulus Reports Fourth Quarter and Year-End 2018 Financial Results and Recent Updates
  10. Regulus Announces Transition of Research Leadership
  11. Regulus Announces Clinical Candidate Nomination for the Treatment of Glioblastoma Multiforme
  12. Regulus Announces Preliminary Results of Planned Interim Data Analysis of RGLS4326 in New Mouse Chronic Toxicity Study
  13. Need To Know: Regulus Therapeutics Inc. (NASDAQ:RGLS) Insiders Have Been Buying Shares
  14. Research Report Identifies Advanced Energy Industries, Altair Engineering, Rambus, Regulus Therapeutics, NN, and Halcon Resources with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
  15. Regulus Presents Preclinical Survival Data Highlighting Potential of Novel Treatment for Glioblastoma Multiforme
  16. Regulus (RGLS) Reports Q3 Loss, Lags Revenue Estimates
  17. Regulus Reports Third Quarter 2018 Financial Results and Recent Updates
  18. Regulus Announces Successful Restructuring of Sanofi Collaboration